<DOC>
	<DOCNO>NCT02345278</DOCNO>
	<brief_summary>Allergic rhinitis/rhinoconjunctivitis symptomatic disorder nose induce immunoglobulin E ( IgE ) mediate inflammatory response . Treatment may involve pharmacotherapy specific immunotherapy ( IT ) . IT represent treatment might alter natural course disease . The amount administer allergen crucial efficacy safety specific IT . SUBLIVAC FIX Mite mixture preparation sublingual IT ( SLIT ) indicate treatment allergic disorder allergic rhinitis rhinoconjunctivitis , cause sensitisation house dust mite ( HDM ) allergens . According European Medicines Agency Guideline clinical development product specific IT treatment allergic disease , product test different dosage provide preliminary data safety tolerability regard maximum tolerate dose suitable dose escalation scheme . This trial design investigate tolerability safety different dosage SUBLIVAC FIX Mite mixture .</brief_summary>
	<brief_title>SUBLIVAC FIX Mite Mixture Dose Tolerability Study</brief_title>
	<detailed_description />
	<criteria>1 . Signed informed consent 2 . Male female patient , age ≥ 18 ≤ 60 year 3 . Patients allergic rhinitis rhinoconjunctivitis induce HDM least 1 year , without concomitant least partly control asthma 4 . Patients history concomitant asthma FEV1 &gt; 70 % ( predict value ) inclusion . Patients without history asthma FEV1 &gt; 70 % PEF &gt; 80 % ( predict value ) 5 . Positive SPT HDM D. pter D. far ( mean wheal diameter ≥ 3 mm compare negative control ; negative control negative ; histamine control positive ( mean wheal diameter ≥ 3 mm ) screen 6 . Allergen specific serum IgE ( ssIgE ) level serum HDM D. pter D. far ( &gt; 0.7 U/ml ) , assess screen 1 . Patients concomitant sensitization i.e . positive SPT ( mean wheal diameter ≥ 3 mm compare negative control ; negative control negative ; histamine control positive ( mean wheal diameter ≥ 3 mm ) expect clinically relevant symptom treatment period 2 . Patients sensitize symptomatic pet regularly expose pet 3 . Completed allergenspecific immunotherapy ( SCIT SLIT ) HDM within last 5 year 4 . Completed unsuccessful allergenspecific immunotherapy ( SCIT SLIT ) within last 5 year 5 . Allergenspecific immunotherapy ( SCIT SLIT ) allergens HDM study period 6 . Any vaccination one week start treatment updosing phase 7 . Any antiIgE therapy within last 6 month prior inclusion study 8 . Active inflammatory disease mouth ( e.g periodontitis , oral mucosal lichen planus ) 9 . Known hypersensitivity excipients ( i.e . Disodium phosphate dihydrate , Sodium dihydrogen phosphate dihydrate , Aminocaproic acid , Glycerol , Peppermint oil , Caramel Colorant ) SLIT solution 10 . Severe immune disorder ( include autoimmune disease ) and/or disease require immunosuppressive drug 11 . Active malignancy malignant disease last 5 year 12 . A chronic acute disease opinion investigator might place patient additional risk , include limited following : cardiovascular insufficiency , severe unstable lung disease , endocrine disorder , clinically significant renal hepatic disease , haematological disorder 13 . Diseases contraindication use adrenaline ( e.g . hyperthyroidism , glaucoma ) 14 . Use systemic corticosteroid 4 week start treatment 15 . Treatment systemic local betablockers 16 . Clinically significant chronic sinusitis ocular infection 17 . Participation clinical study new investigational drug within last 3 month biological within last 6 month prior study study 18 . Pregnancy , lactation inadequate contraceptive measure ( acceptable form birth control include Intrauterine device hormonal contraception ( oral contraceptive pill , implant , transdermal patch , vaginal ring longacting injection ) condom combine diaphragm include spermicidal cream ) . Also acceptable woman surgical sterilization ( removal uterus ovary tubal ligation ( `` tie tube '' ) ) , postmenopausal ( 12 consecutive month without period ) least 2 year , sexual relationship man . 19 . Alcohol , drug , medication abuse within past year study 20 . Any lack cooperation compliance 21 . Severe psychiatric , psychological , neurological disorder 22 . Patients employee department study site ; 1st grade relative , partner investigator , patient dependent sponsor 23 . Any physical mental condition precludes administration allergenspecific immunotherapy , compliance participation trial 24 . Patients placed institution due governmental judicial directive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Allergic rhinitis/rhinoconjunctivitis</keyword>
</DOC>